NeoGenomics (NASDAQ:NEO - Get Free Report) posted its quarterly earnings data on Tuesday. The medical research company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.06), Zacks reports. NeoGenomics had a negative net margin of 11.92% and a negative return on equity of 2.10%. The business had revenue of $168.04 million for the quarter, compared to the consensus estimate of $171.38 million. During the same quarter last year, the business posted ($0.02) EPS. The business's revenue for the quarter was up 7.6% on a year-over-year basis. NeoGenomics updated its FY 2025 guidance to EPS.
NeoGenomics Stock Up 6.1 %
NASDAQ:NEO traded up $0.44 during trading hours on Friday, reaching $7.70. The company's stock had a trading volume of 3,644,552 shares, compared to its average volume of 1,076,374. NeoGenomics has a one year low of $6.08 and a one year high of $19.12. The business's 50-day moving average is $9.40 and its 200-day moving average is $13.26. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.98 and a quick ratio of 1.91. The company has a market cap of $990.66 million, a price-to-earnings ratio of -12.42 and a beta of 1.41.
Analyst Ratings Changes
NEO has been the subject of a number of recent analyst reports. Leerink Partners lowered NeoGenomics from an "outperform" rating to a "market perform" rating and decreased their price target for the company from $25.00 to $9.00 in a research report on Wednesday. Bank of America dropped their target price on shares of NeoGenomics from $19.00 to $16.00 and set a "neutral" rating on the stock in a research report on Wednesday, February 19th. Needham & Company LLC decreased their price objective on shares of NeoGenomics from $18.00 to $8.50 and set a "buy" rating for the company in a research note on Tuesday, April 29th. The Goldman Sachs Group reduced their target price on NeoGenomics from $15.00 to $10.00 and set a "buy" rating for the company in a report on Wednesday. Finally, Piper Sandler lowered their price target on NeoGenomics from $21.00 to $18.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. Five equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $14.50.
Get Our Latest Research Report on NEO
NeoGenomics Company Profile
(
Get Free Report)
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
See Also
Before you consider NeoGenomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeoGenomics wasn't on the list.
While NeoGenomics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
